EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Refractory Dermatomyositis Treated With Anifrolumab: Clinical Response and Dynamics of Type-I Interferon Signature

M E Gimeno-Ribes, A Mensa-Vilaro, J I Aróstegui, S Prieto-González, J C Milisenda, X Bosch-Amate, J M Mascaró

Actas Dermo-Sifiliográficas · 2026

DOI: 10.1016/j.ad.2026.104679 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Actas Dermo-Sifiliográficas, 2026. Verfasst von M E Gimeno-Ribes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain. Electronic address: gimenoribes.mariaelena@gmail.…. Hauptthemen laut MEDLINE: Dermatomyositis, Antibodies, Monoclonal, Humanized, Interferon Type I. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dermatomyositis (DM) is a systemic inflammatory disease predominantly affecting the skin and muscles, with potential involvement of internal organs. Despite multiple therapeutic options, treatment response may be unsatisfactory. Type-I interferon (IFN) signaling pathways have been proposed as key drivers of disease pathogenesis. Consequently, treatment with anifrolumab, a monoclonal antibody targeting IFN receptor-1, may offer therapeutic benefit. To date, only a few cases of refractory DM successfully treated with anifrolumab have been reported. We present two cases of refractory DM treated with anifrolumab achieving an almost complete cutaneous response. Longitudinal evaluation of the type-I IFN signature revealed a decrease during treatment. These findings support the hypothesis that type-I IFN plays a pathogenic role in DM, especially in patients with refractory disease. In this context, we aim to highlight the importance of considering anifrolumab as a therapeutic option and underscore the potential of the IFN signature as a biomarker of treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisAntibodies, Monoclonal, HumanizedInterferon Type IHumansFemaleMaleMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

AnifrolumabDermatomyositisTofacitinibType-I interferon signature

Substanzen

Antibodies, Monoclonal, HumanizedInterferon Type Ianifrolumab

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain. Electronic address: gimenoribes.mariaelena@gmail.com.
  • Department of Immunology, Hospital Clínic de Barcelona-IDIBAPS, University of Barcelona, Spain.
  • Department of Autoimmune Diseases, Hospital Clínic de Barcelona, University of Barcelona, Spain.
  • Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.

Förderung

  • Instituto de Salud Carlos III
  • European Commission

Zitieren

APA

Gimeno-Ribes, M. E., Mensa-Vilaro, A., Aróstegui, J. I., Prieto-González, S., Milisenda, J. C., Bosch-Amate, X., & Mascaró, J. M. (2026). Refractory Dermatomyositis Treated With Anifrolumab: Clinical Response and Dynamics of Type-I Interferon Signature. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2026.104679

Vancouver

Gimeno-Ribes ME, Mensa-Vilaro A, Aróstegui JI, Prieto-González S, Milisenda JC, Bosch-Amate X, et al. Refractory Dermatomyositis Treated With Anifrolumab: Clinical Response and Dynamics of Type-I Interferon Signature. Actas Dermo-Sifiliográficas. 2026. doi:10.1016/j.ad.2026.104679

BibTeX
@article{GimenoRibes2026,
  author = {Gimeno-Ribes, M E and Mensa-Vilaro, A and Aróstegui, J I and Prieto-González, S and Milisenda, J C and Bosch-Amate, X and Mascaró, J M},
  title = {Refractory Dermatomyositis Treated With Anifrolumab: Clinical Response and Dynamics of Type-I Interferon Signature},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2026},
  doi = {10.1016/j.ad.2026.104679}
}
Kostenlos starten →